source
- UCSF spinout Kopra Bio secures $9.1M to advance virus therapy for glioblastoma in ChinaKopra Bio, a biotechnology company spun out of the University of California, San Francisco, announced it has raised $9.1 million in financing. The capital will be used to move its experimental viru…
- Be Bio halts hemophilia B cell-editing therapy trialBe Bio announced that it has terminated its clinical study of a hemophilia B therapy that used gene-editing of a patient’s own cells. The termination was recorded in a federal clinical-trials regi…